PhRMA welcomes US Congressional support for Pediatric Reauthorization ACT

US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) has welcomed the bipartisan support for the BPCA and PREA Reauthorization Act of 2012 in the House of Representatives and for the Senate’s Better Pharmaceuticals and Devices for Children Act of 2012, both of which would permanently reauthorize the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).

David Wheadon, PhRMA senior vice president for scientific and regulatory Affairs, commented: “BPCA and PREA have been exceedingly successful in improving medical care for children by driving research to create innovative medicines for use in pediatric patients. Prior to their passage, roughly 70 percent of medicines taken by children lacked pediatric dosing information. As of 2008, thanks to BPCA and PREA, between 50% and 60% of medicines have been studied in some part of the pediatric population.”

Will provide certainty for pediatric studies